Under the agreement, Kody Technolab has been appointed the exclusive worldwide manufacturer of the Medigo platform. Falcon Tech Robotics will serve as the exclusive global distributor, while Sccore AI Tech Diagnostic Limited will undertake worldwide deployment and commercialization of the products. The engagement is structured for execution over a three-year period, with manufacturing and supply of Medigo units scheduled to commence during the first half of financial year 2026-27 and continue throughout the agreement term.
The arrangement is supported by a binding minimum purchase framework structured across biannual commercial periods, providing Kody Technolab with enhanced commercial visibility during the tenure of the agreement.
The development places Kody Technolab at the centre of one of the healthcare sector's largest unmet needs and one of its fastest-growing markets. According to the World Health Organization and the World Bank, nearly 4.5 billion people, representing more than half of the world's population, do not have full access to essential health services. Industry estimates indicate that the global preventive healthcare market is expected to expand from approximately USD 268.7 billion in 2023 to USD 585.6 billion by 2030, creating a substantial opportunity for autonomous healthcare screening platforms such as Medigo.
The agreement establishes a comprehensive commercial structure covering manufacturing, global distribution and international deployment of Kody Technolab's medical robotics platform. Kody Technolab will exclusively manufacture the products worldwide, while Falcon Tech Robotics LLC, the company's UAE-based joint venture, will handle global distribution and commercial coordination. Sccore AI Tech Diagnostic Limited will oversee deployment and commercialization across international markets.
The Medigo range comprises four artificial intelligence-powered healthcare screening robots designed to deliver clinical-grade preventive screening within minutes without relying on specialized medical personnel.
Medigo Static is a stationary autonomous health screening robot developed for fixed installations in primary health centres, corporate campuses, public institutions and other high-footfall locations. Medigo Kids is a paediatric screening robot specifically designed for children's health assessments in schools, paediatric clinics and community child health programmes. Medigo Women is a dedicated women's health screening robot focused on gender-specific preventive examinations covering maternal, reproductive and wellness parameters. Medigo Mobile is a mobile robotic health screening platform engineered for last-mile deployments, transit hubs, rural outreach operations and crowded public locations.
Each unit is capable of screening a broad range of metabolic, cardiovascular, infectious, sensory and mental health conditions. The systems generate consolidated reports within minutes in the patient's preferred language and provide real-time anonymized data to institutional and government health dashboards.
The agreement marks a major milestone in Kody Technolab's strategy to expand its healthcare robotics business globally and strengthens its strategic presence across the United Arab Emirates and other international markets. By combining Kody Technolab's engineering capabilities with Falcon's regional network and Sccore's deployment expertise, the tripartite structure aims to establish Medigo-based screening infrastructure across multiple geographies, reinforcing the company's position in artificial intelligence-driven healthcare robotics.
The Board of Directors believes the engagement represents an important step in Kody Technolab's international growth plans and reflects increasing commercial demand for the company's medical robotics platform.
Commenting on the development, Manav Subhashchandra Patel, Managing Director of Kody Technolab Limited, said the agreement represents a defining moment in the company's efforts to scale its healthcare robotics platform globally. He stated that the Medigo range has been designed to address diverse screening requirements across populations, demographics and healthcare environments. He added that the structure involving exclusive worldwide manufacturing, global distribution through the UAE joint venture and deployment by Sccore provides a strong route to international markets. According to him, the agreement marks the beginning of long-term deployments across multiple geographies and demonstrates the company's commitment to delivering quality, scale and speed.
Prashant Sawant, Chairman and Managing Director of Sccore AI Tech Diagnostic Limited, said the company is proud to partner with Kody Technolab and Falcon Tech Robotics in introducing the Medigo platform to international markets. He stated that access to timely and affordable preventive screening remains one of the world's most pressing healthcare challenges and that Medigo's clinical-grade screening capabilities, multilingual interaction and real-time data systems provide a highly scalable solution. He added that Sccore looks forward to large-scale deployments across diverse healthcare environments through a long-term partnership with Kody Technolab and Falcon.
Kody Technolab Limited is a deep technology company specializing in autonomous robotics solutions and artificial intelligence-driven automation for commercial, retail and industrial sectors. The company develops scalable robotic platforms with expertise in software engineering, autonomous navigation and intelligent systems, supporting major deployments across the Middle East and Asia.
Falcon Tech Robotics LLC is a United Arab Emirates-based joint venture between Kody Technolab Limited and Platinum Group for Businessmen Services LLC. The company focuses on accelerating robotics adoption throughout the Middle East by deploying advanced artificial intelligence-powered robotic solutions supported by Kody Technolab's technology and Platinum Group's regional presence.
Sccore AI Tech Diagnostic Limited is a United Arab Emirates-based company engaged in the deployment and commercialization of artificial intelligence-powered diagnostic and healthcare technologies across global markets.
The company stated that the release contains forward-looking statements relating to plans, prospects, execution timelines and market estimates, which are subject to risks and uncertainties. Actual results may differ materially, and the company has indicated that it undertakes no obligation to publicly update such statements.
The landmark agreement signals a significant expansion of Kody Technolab's global healthcare robotics ambitions and positions the Medigo platform to address growing international demand for accessible, technology-driven preventive healthcare infrastructure.
About The Author
Comment List